Shire PLC (NASDAQ:SHPG) – Investment analysts at SunTrust Banks boosted their FY2018 earnings estimates for shares of Shire PLC in a research report issued to clients and investors on Thursday. SunTrust Banks analyst J. Boris now forecasts that the brokerage will post earnings of $18.78 per share for the year, up from their previous forecast of $18.76.
Several other equities research analysts have also recently issued reports on the company. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. Jefferies Group reissued a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a research note on Wednesday, September 7th. TheStreet cut Shire PLC to a “hold” rating in a research note on Thursday, August 4th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire PLC in a research note on Monday, September 26th. Finally, Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research note on Friday, July 15th. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $232.75.
Shire PLC (NASDAQ:SHPG) traded up 0.55% during midday trading on Monday, reaching $196.52. The company’s stock had a trading volume of 305,168 shares. The firm has a market cap of $58.53 billion, a price-to-earnings ratio of 40.84 and a beta of 1.16. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The company’s 50-day moving average is $196.04 and its 200 day moving average is $186.49.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. During the same quarter last year, the business posted $2.63 EPS. The business’s revenue was up 55.9% on a year-over-year basis.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be given a dividend of $0.139 per share. The ex-dividend date is Wednesday, September 7th. Shire PLC’s payout ratio is presently 15.63%.
Several institutional investors have recently added to or reduced their stakes in SHPG. Canal Insurance CO purchased a new position in Shire PLC during the second quarter valued at about $102,000. FTB Advisors Inc. increased its position in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. purchased a new position in Shire PLC during the second quarter valued at about $111,000. Quadrant Capital Group LLC increased its position in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC purchased a new position in Shire PLC during the second quarter valued at about $114,000. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.